Trial intelligence / Profile preview

Bioequivalence of Two Dabigatran Etexilate Generations

NCT02171520Phase 1Completed

Sponsor
Boehringer Ingelheim
Start
May 2008
Primary completion
Aug 2008
Modality
Small Molecules
01

Overview

Phase 1, randomised, double-blind trial of dabigatran in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of total dabigatran in plasma from 0 to infinity and Maximum measured concentration of total dabigatran in plasma. Started May 2008; status: completed.

02

Drugs

dabigatran
03

Conditions

thromboembolism

Beyond the preview

Go deeper on NCT02171520.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02171520.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call